SCHEMBL19203362

SCHEMBL19203362

c1ccc2oc(-c3ccc4cc(-c5ccc6ocnc6c5)[nH]c4c3)cc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT3 O60678 1/20 0.46
EHMT2 Q96KQ7 1/20 0.46
PRMT6 Q96LA8 1/20 0.46
PRMT1 Q99873 1/20 0.46
PRMT8 Q9NR22 1/20 0.46
DYRK1A Q13627 1/20 0.42
ALOX5 P09917 1/20 0.40
MAOB P27338 3/20 0.39
ADRA2A P08913 2/20 0.39
KDM5A P29375 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
KDM5B Q9UGL1 1/20 0.38
MAOA P21397 2/20 0.38
PTPRC P08575 1/20 0.38
PTPN1 P18031 1/20 0.38
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22917376 0.82 ADRA2A (0.44) DYRK1AALOX5MAOBADRA2AMAOA
SCHEMBL20121979 0.81 KDM4E (0.52) PRMT3EHMT2PRMT6PRMT1PRMT8
SCHEMBL20022978 0.81 DYRK1A (0.43) PRMT1DYRK1AALOX5MAOBADRA2A
SCHEMBL20625822 0.76 GRM4 (0.44) PRMT3EHMT2PRMT6PRMT1PRMT8
SCHEMBL19287942 0.76 ESR1 (0.48) DYRK1ANPC1RAB9AKDM4EALDH1A1
SCHEMBL19425952 0.75 FOXO1 (0.44) DYRK1ANPC1RAB9AKDM4EALDH1A1
SCHEMBL20469630 0.74 ADRA2A (0.45) DYRK1AALOX5MAOBADRA2AMAOA
SCHEMBL19087492 0.73 ALOX5 (0.43) PRMT1DYRK1AALOX5MAOBADRA2A
SCHEMBL21099202 0.73 NPC1 (0.50) DYRK1ANPC1RAB9ACA1CA2
SCHEMBL18457192 0.73 GRM4 (0.53) PRMT3EHMT2PRMT6PRMT1PRMT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10166215-B2 Substituted bicyclic compounds as bromodomain inhibitors ZENITH EPIGENETICS LTD. (CA) 2019-01-01 US disclosed
US-9999616-B2 2018-06-19 US disclosed
US-20170216257-A1 NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS RVX THERAPEUTICS INC. (CA) 2017-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10166215-B2 Substituted bicyclic compounds as bromodomain inhibitors BRD4, BRD3, BRD2 PRMT3 642/4885EHMT2 319/4885PRMT6 894/4885
US-20170216257-A1 NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRD2 PRMT3 775/4885EHMT2 412/4885PRMT6 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.